10768
0
Posted on Oct 22, 2018, 10 p.m.
Antiphospholipid antibody levels are elevated in myocardial infarction without any autoimmune co-morbidity, as published in The Annals of Internal Medicine.
800 participants from 17 hospitals were involved in this study conducted by Karolinska Institutet researchers. Patients had suffered their first myocardial infarction, their blood was analysed for 6-10 weeks for 3 different antiphospholipid antibody types: immunoglobulin G (IgG); M (IgM); and A (IgA). 11% of subjects were found to have antiphospholipid antibodies against both cardiolipin and ?2glycoprotein-1, amounts that are 10 times higher than that of controls. Increase was only found in the IgG antibodies that are considered to be most associated with blood clots.
It was noted that the measurement was only done on an single occasion, so it is not impossible that it may reflect temporary reactions to the infarction. Should levels of antiphospholipid antibody levels remain elevated for a further 3 months, by definition those patients have APS; in which case according to current recommendations they should be prescribed lifelong treatments with anticoagulants to reduce risks of new blood clots; which would change prevailing guidelines for the investigation and treatment of heart attacks, says Professor Elisabet Svenungsson.
Materials provided by Karolinska Institutet.
Note: Content may be edited for style and length.
Journal Reference:
Giorgia Grosso, Natalie Sippl, Barbro Kjellström, Khaled Amara, Ulf de Faire, Kerstin Elvin, Bertil Lindahl, Per Näsman, Lars Rydén, Anna Norhammar, Elisabet Svenungsson. Antiphospholipid Antibodies in Patients with Myocardial Infarction. Annals of Internal Medicine, 23 October 2018 DOI: 10.7326/M18-2130
